Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Su, Zhen"'
Autor:
Xinyue Hu, Xiujun Liu, Lianqi Sun, Yong-Su Zhen, Yi Li, Jie Jin, Yanping Li, Yu‐cheng Wang, Qingfang Miao, Rong Wang, Zhuorong Li, A-Long Cui
Publikováno v:
Molecular Oncology
Molecular Oncology, Vol 13, Iss 2, Pp 246-263 (2019)
Molecular Oncology, Vol 13, Iss 2, Pp 246-263 (2019)
Epidermal growth factor receptor (EGFR) is a rational target for cancer therapy, because its overexpression plays an important oncogenic role in a variety of solid tumors; however, EGFR-targeted antibody-drug conjugate (ADC) therapy for esophageal sq
Publikováno v:
Oncotarget
// Bing-yan Zhu 1 , Bo-yang Shang 1 , Yue Du 1 , Yi Li 1 , Liang Li 1 , Xian-dong Xu 1 , Yong-su Zhen 1 1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China Correspondence
Autor:
Xian-dong Xu, Zhi-Ling Zhu, Xiujun Liu, Boyang Shang, Shuying Wu, Yi Li, Shuyi Si, Yong-Su Zhen, Yan-Bo Zheng, Jinming Zhou, Jian-Hua Gong
Publikováno v:
Scientific Reports
Multidrug resistance is a major limitation for microtubule-binding agents in cancer treatment. Here we report a novel microtubule inhibitor (2-morpholin-4-yl-5-nitro-benzoic acid 4-methylsulfanyl-benzyl ester, IMB5046), its cytotoxicity against multi